Ruxolitinib Combined With Hematopoietic Cell Transplantation May Improve Survival in MF
Sept. 11 - The use of ruxolitinib with allogeneic hematopoietic cell transplantation (HCT) demonstrates safety and tolerability, while potentially lowering the risk of graft-versus-host disease (GVHD) and enhancing survival in patients with myelofibrosis (MF), based on results from a phase 2 study published in JCO Oncology Advances.